首页> 外文期刊>Medical science monitor : >Cyclophosphamide pulses - intravenous treatment in patients with primary glomerulonephritis
【24h】

Cyclophosphamide pulses - intravenous treatment in patients with primary glomerulonephritis

机译:环磷酰胺脉冲-原发性肾小球肾炎患者的静脉内治疗

获取原文
           

摘要

The aim of the study was an evaluation of cyclophosphamide pulses treatment in 6 nephrotic syndrome patients with primary glomerulonephritis without renal failure but with contraindications to a steroid therapy. The medicine was given once a month, in 12 intravenous doses, 1000 mg each. After 6 month of this treatment an oedema disappeared and daily proteinuria decreased (from 13.8+-10.2g to 4.8+-4.4g) in all patients.The only observed side effects were as follows: nausea in 1 person and minimal transient increase of serum aminotransferases in all patients. In one year follow up (in 4 still observed patients) after this treatment, daily proteinuria was less than 1.0 g and kidneys were still sufficient. Conclusion: We propose such therapy as effective, safe and well tolerated.
机译:该研究的目的是评估6例原发性肾小球肾炎,无肾功能衰竭但有类固醇治疗禁忌症的肾病综合征患者的环磷酰胺脉冲治疗。该药物每月一次,以12剂静脉注射,每次1000毫克。该治疗6个月后,所有患者的水肿消失,每日蛋白尿减少(从13.8 + -10.2g降至4.8 + -4.4g)。唯一观察到的副作用如下:1人恶心,血清短暂升高所有患者的转氨酶。经过一年的随访(4例仍观察到的患者),每日蛋白尿少于1.0 g,肾脏仍然足够。结论:我们建议这种治疗有效,安全且耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号